Myosin Therapeutics Receives Significant Grant
Myosin Therapeutics, Inc., an innovative biotechnology company specializing in treatments for cancer and neurological disorders, has secured a substantial $3 million grant. This funding, awarded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), is aimed at propelling the development of MT-110, a promising therapeutic option for individuals grappling with methamphetamine use disorder (MUD).
Exploring the Clinical Trial of MT-110
The newly awarded grant is intended to initiate a Phase 1 clinical trial. This trial will focus on evaluating the safety, tolerability, and pharmacokinetics of MT-110, paving the way for its application as a novel treatment for MUD. Currently, MUD represents a major public health issue, with over 2.5 million individuals affected in the United States alone. The absence of FDA approved treatments for this disorder amplifies the urgency of this endeavor as overdose deaths related to methamphetamine are on the rise.
NIDA's Support Through SBIR Program
This grant stems from the Small Business Innovation Research (SBIR) program, designed to support the advancement of promising technologies with significant public health implications. This competitive initiative not only accelerates translational science but also addresses critical gaps in treatment options for substance use disorders, highlighting the potential of MT-110.
Expert Insights on the MT-110 Development
Dr. Pat Griffin, co-founder of Myosin Therapeutics, expressed heartfelt gratitude towards NIDA for their ongoing support. "There are currently no FDA-approved medications for methamphetamine use disorder, and we believe MT-110 has the potential to fill this critical unmet need," he stated. This level of company commitment represents a significant step toward addressing a severe health crisis.
MT-110 was developed as part of NIH's Blueprint Neurotherapeutics Network, which facilitates collaboration between public and private sectors to advance drug development. This partnership has enabled the journey of MT-110 from its initial discovery to readiness for clinical trials.
The Promise of MT-110 in Combating MUD
MT-110 operates by targeting a crucial molecular nanomotor protein, specifically designed to reduce the motivation for stimulant usage and curb relapses, all while sparing natural reward pathways. Encouraging preclinical research has demonstrated impressive safety and efficacy, highlighting the potential for successful human trials.
Addressing the Challenges of Methamphetamine Use Disorder
Dr. Karen Smith, Chief Medical Officer of Myosin Therapeutics, emphasized the widespread devastation that methamphetamine use disorder inflicts on individuals and communities. She noted that existing treatment options predominantly consist of behavioral strategies, underscoring the need for effective pharmacological interventions. MT-110's prolonged efficacy in preclinical trials, noted after a singular administration, signifies its potential as a viable solution, particularly in a population where adherence to daily medication regimens may be challenging.
About Myosin Therapeutics
Myosin Therapeutics is based in Jupiter, FL, and emerged from The Wertheim UF Scripps Institute. The company was co-founded in 2020 by a team of experts: Drs. Courtney Miller, Patrick Griffin, and Theodore Kamenecka. They are committed to developing innovative therapies targeting conditions in neuroscience and oncology, harnessing a unique drug discovery platform focused on molecular nanomotor proteins.
Frequently Asked Questions
What is MT-110?
MT-110 is an innovative therapeutic agent being evaluated for the treatment of methamphetamine use disorder.
How much funding did Myosin Therapeutics receive?
Myosin Therapeutics received a $3 million grant from the National Institute on Drug Abuse.
What will the grant be used for?
The grant will support a Phase 1 clinical trial to evaluate the safety and effectiveness of MT-110.
Who is leading the development of MT-110?
The project is led by Myosin Therapeutics' co-founders, including Dr. Pat Griffin and Dr. Karen Smith.
Why is MT-110 important?
MT-110 could fill a critical gap in treatment for methamphetamine use disorder, addressing a significant public health issue with increasing overdose rates.
